Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, September 17, 2024
Recipharm announced a significant investment in its Oral Solid Development and Pilot Scale Centre in Zwickau, Germany. The investment includes three new GMP Pilot Scale suites for blending, tableting and hard capsule filling, which will complement ...
read more
Thursday, December 20, 2018
Recipharm announced that it will explore the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK.
read more
Recipharm, the contract development and manufacturing organization (CDMO), has announced a 5 million SEK investment into a new GLP (Good Laboratory Practice) compliant bioanalysis laboratory at its development facility in Uppsala, Sweden, in response...
read more
Recipharm is expanding its pMDI product development expertise to accommodate the increasing demand from pharmaceutical companies as they begin the transition to the next generation of propellants over the coming years. These new propellant gases have...
read more
Thursday, November 09, 2017
Recipharm will initiate a process with the intention of discontinuing manufacturing operations at its facilities in Stockholm and Höganäs, Sweden.
read more
Tuesday, October 20, 2015
The contract development and manufacturing organisation, Recipharm AB has entered into an agreement whereby it will acquire a majority stake in Nitin Lifesciences Limited, an Indian sterile injectables CMO, currently owned by the Sobti family.
read more
Wednesday, February 24, 2016
Recipharm AB has entered into an agreement to acquire Italian CDMO, Mitim Srl adding scale and capabilities to the group. Mitim is currently owned by a private Italian family and is specialized in the filling of injectable beta lactam products. It ...
read more
Wednesday, February 13, 2013
Recipharm and PledPharma announce FDA approval of an IND application for Phase IIb clinical trial with PledOx, PLIANT, in the U.S. The material for PLIANT has been manufactured by Recipharm Pharmaceutical Development.
read more
Friday, December 20, 2013
RPH Pharmaceuticals AB, a subsidiary of Recipharm AB, announces the filing of an application for an infectious disease drug product in a range of European countries. The product has been developed through a partnership with Swedish pharmaceutical ...
read more
Thursday, October 20, 2022
Recipharm has invested in a new high-speed filling line for pre-filled syringes and cartridges at its facility in Wasserburg, Germany responding to increased customer demand in these high-growth fill formats.
read more
Wednesday, December 23, 2015
Recipharm has entered into the previously announced strategic collaboration with Alcon, a Novartis company, and has signed a long term supply agreement whereby Recipharm will manufacture a range of ophthalmic products using Blow Fill Seal technology.
read more
Wednesday, January 20, 2021
Recipharm and Enzymatica have signed a broadened contract for the manufacture of ColdZyme.
read more
Wednesday, September 20, 2017
Recipharm has entered into collaboration with Roche and signed a long-term manufacturing agreement whereby Recipharm will manufacture a range of solid dose products.
read more
Wednesday, August 26, 2015
Recipharm AB has signed an agreement with Israeli biopharmaceutical company RedHill Biopharma Ltd for the manufacturing of RedHill’s leading, late-stage patented drug candidate, RHB-105.
read more
The company earmarks new EUR 90 million loan facility for further acquisition of niche CDMOs, investment in existing facilities and building long term partnerships with major pharmaceuticals companies.
read more